This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to ...

On Tuesday, Fujifilm Diosynth announced a 10-year agreement worth more than $3 billion to make medicines for the New York drugmaker Regeneron in the Triangle. Regeneron is the facility’s third major ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

Regeneron Pharmaceuticals, Inc. (REGN) announced on Tuesday that it has entered into a manufacturing and supply agreement ...

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

Agreement secures additional U.S. manufacturing capacity to help ensure patient access to medicineHOLLY SPRINGS, N.C., April 23, 2025 -- ...